Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| American Well CorpAMWL · Entity 2112 | Director | June 22, 2023 | June 26, 2023 |
| COCA COLA CO(KO) · Entity 2806 | Executive Vice President | November 19, 2004 | November 23, 2004 |
| GreenLight Biosciences Holdings, PBCGRNA · Entity 111075 | See Remarks | July 24, 2023 | July 26, 2023 |
| SpringWorks Therapeutics, Inc.SWTX · Entity 15910 | Director | September 12, 2019 | September 12, 2019 |
| TWILIO INCTWLO · Entity 3109 | Director | September 15, 2026 | September 17, 2026 |
| Toast, Inc.TOST · Entity 3272 | Director | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
American Well Corp
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 169,892 |
Reported balance
After 2023-06-22 transaction · row 1
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 91,743 · Balance 169,892 F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Wife | 8,000 |
Reported balance
Holding disclosure · report date 2023-06-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date.
COCA COLA CO
Report date November 19, 2004 · Filed November 23, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 par valueSEC Table I · non-derivative | Direct | 39,084 |
Reported balance
After 2004-11-19 transaction · row 1
1 source rowRow 1 · 2004-11-19 · Sale · Disposed 13,100 · Balance 39,084 |
| Common Stock, $.25 par valueSEC Table I · non-derivative | IndirectBy 401(k) plan | 414 |
Reported balance
Holding disclosure · report date 2004-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 414 F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004. |
| Common Stock, $.25 par valueSEC Table I · non-derivative | IndirectBy daughter | 50 |
Reported balance
Holding disclosure · report date 2004-11-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 50 |
| Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Deferred Compensation Plan | 602 |
Reported balance
Holding disclosure · report date 2004-11-19 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 602 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F4: Excess 401(k) as of November 18, 2004. |
| Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Supplemental Benefit Plan | 2,183 |
Reported balance
Holding disclosure · report date 2004-11-19 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,183 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F5: As of November 18, 2004. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004.
F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company.
F3: There is no data applicable with respect to the hypothetical shares.
F4: Excess 401(k) as of November 18, 2004.
F5: As of November 18, 2004.
GreenLight Biosciences Holdings, PBC
Report date July 24, 2023 · Filed July 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-24 transaction · row 1
1 source rowRow 1 · 2023-07-24 · Other · Disposed 172,500 · Balance 0 F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.
SpringWorks Therapeutics, Inc.
Report date September 12, 2019 · Filed September 12, 2019
This filing explicitly reported no securities owned.
TWILIO INC
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 19,055 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 337 · Balance 19,055 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2: Includes RSUs that have been deferred by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant.
F2: Includes RSUs that have been deferred by the Reporting Person.
Toast, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Exercise / conversion · Disposed 5,256 · Balance 0 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F2: The RSUs vested in full on June 12, 2026. F3: Not Applicable. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,888 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Grant · Acquired 8,888 · Balance 8,888 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3: Not Applicable. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 14,968 |
Reported balance
After 2026-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-12 · Exercise / conversion · Acquired 5,256 · Balance 14,968 F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member. F3: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement.
F2: The RSUs vested in full on June 12, 2026.
F3: Not Applicable.
F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member.
F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 3,282 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 49,794 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 9,037 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 625 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2018 Filed Jul 10, 2018 22:13 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 42,379 | $43.40 | $1,839,282.50 |
DisclosureSEC source: 0000899243-18-019720 · doc4.xml · nonDerivative · entry 5 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average sale price of the shares sold ranging from $43.35 to $43.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 22:13 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 4,018 | $3.40 | $13,661.20 |
DisclosureSEC source: 0000899243-18-019720 · doc4.xml · nonDerivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 22:13 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 8,361 | $20.00 | $167,220.00 |
DisclosureSEC source: 0000899243-18-019720 · doc4.xml · nonDerivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 22:13 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000899243-18-019720 · doc4.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 22:13 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 15,000 | $28.45 | $426,750.00 |
DisclosureSEC source: 0000899243-18-019720 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $42.25 | $0.00 |
DisclosureSEC source: 0000899243-18-017765 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0000899243-17-019200 · doc4.xml · derivative · entry 5 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares vested and became exercisable in 12 equal monthly installments, with the first installment on July 16, 2016, subject to the recipient's continued service on the Issuer's Board of Directors. This option was subject to accelerated vesting upon a change of control of the Issuer. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,053 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-019200 · doc4.xml · derivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 12,053 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 27,053 | $29.69 | $803,203.57 |
DisclosureSEC source: 0000899243-17-019200 · doc4.xml · nonDerivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 15,000 | $18.85 | $282,750.00 |
DisclosureSEC source: 0000899243-17-019200 · doc4.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 12,053 | $3.40 | $40,980.20 |
DisclosureSEC source: 0000899243-17-019200 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2017 Filed Jun 23, 2017 01:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.45 | $0.00 |
DisclosureSEC source: 0000899243-17-016993 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document |
| November 19, 2004 Filed Nov 23, 2004 17:52 UTC | COCA COLA CO (KO) · Entity 2806 | SaleCommon Stock, $.25 par value | 13,100 | $40.19 | $526,489.00 |
DisclosureSEC source: 0000021344-04-000189 · pat36.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,084 Read SEC document |
| April 19, 2004 Filed May 18, 2004 19:59 UTC | COCA COLA CO (KO) · Entity 2806 | Tax withholdingCommon Stock, $.25 par value | 21,417 | $52.90 | $1,132,959.30 |
DisclosureSEC source: 0000021344-04-000067 · pat34.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,184 F1 · kind: Shares withheld by the issuer to pay taxes on the lapse of restrictions on restricted stock. Read SEC document |
| December 18, 2003 Filed Dec 22, 2003 21:46 UTC | COCA COLA CO (KO) · Entity 2806 | GrantEmployee Stock Option (right to buy) · Derivative | 112,000 | $0.00 Strike: $49.80 | $0.00 |
DisclosureSEC source: 0000021344-03-000207 · pat29.xml · derivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock, $.25 par value · 112,000 shares Expires 2013-12-17 F2 · derivative.exercise_date: Option (with tax withholding right) granted on December 18, 2003 under The Coca-Cola Company 2002 Stock Option Plan. One-fourth of grant becomes exercisable on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.